TNF Pharmaceuticals Reports Q2 2025 Financial Results with Reduced Net Loss

TNF Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $1.8 million, a significant reduction from the $9.6 million loss recorded in the same period last year. For the six months ending June 30, 2025, the company reported a net loss of $2.9 million, compared to a loss of $19.4 million for the first half of 2024. The company continues to operate without generating any product revenue, as it is still in the clinical development phase for its lead product candidates, Isomyosamine and Supera-CBD.

Total operating expenses for the second quarter of 2025 were approximately $1.9 million, down from $3.4 million in the prior year. The decrease was primarily attributed to lower administrative expenses, which fell to $894,297 from $1 million, and a reduction in research and development costs, which increased to $873,472 from $401,104, reflecting ongoing investments in clinical trials. The company’s stock-based compensation expenses also decreased significantly, from $439,627 in Q2 2024 to $104,854 in Q2 2025.

In terms of strategic developments, TNF Pharmaceuticals has been actively pursuing clinical trials for Isomyosamine, which is being evaluated for its potential to treat age-related frailty and sarcopenia. The company announced the initiation of a Phase 2b clinical trial in February 2024 and has since partnered with Renova Health to leverage AI technologies for patient recruitment. Additionally, the company has formed a collaboration with the DADA2 Foundation to explore Isomyosamine as a treatment for a rare inflammatory disease.

As of June 30, 2025, TNF Pharmaceuticals had total assets of $17.2 million, down from $21.4 million at the end of 2024. The company’s cash and marketable securities totaled $3.8 million, with a working capital deficit of $397,585. The company’s stockholders’ equity stood at $5.3 million, which includes an accumulated deficit of $133.8 million. The company has indicated that it will need to secure additional capital to continue its operations and fund its clinical development efforts, raising concerns about its ability to continue as a going concern.

Looking ahead, TNF Pharmaceuticals is focused on advancing its clinical programs and securing additional funding. The company has been primarily financed through the sale of preferred stock and common stock, and it may seek further private equity or debt financing to support its operations. The company’s ability to maintain its listing on the Nasdaq Capital Market is contingent upon meeting minimum bid price requirements, which adds another layer of urgency to its capital-raising efforts.